SARS-CoV-2 in inflammatory bowel disease population: Antibodies, disease and correlation with therapy.
Biologic treatment
COVID-19
Inflammatory bowel disease
Inflammatory bowel disease therapy
SARS-CoV-2
SARS-CoV-2 antibody
Journal
World journal of gastrointestinal endoscopy
ISSN: 1948-5190
Titre abrégé: World J Gastrointest Endosc
Pays: United States
ID NLM: 101532474
Informations de publication
Date de publication:
16 Mar 2022
16 Mar 2022
Historique:
received:
11
10
2021
revised:
14
12
2021
accepted:
16
02
2022
entrez:
18
4
2022
pubmed:
19
4
2022
medline:
19
4
2022
Statut:
ppublish
Résumé
Guidelines recommend to cease inflammatory bowel disease (IBD) biologic therapy during coronavirus disease 2019 (COVID-19). To investigate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody positivity in an IBD cohort, COVID-19 disease severity and to evaluate the correlation with clinical/therapeutic variables. Prospective observational cohort study. IBD patients were tested for SARS-CoV-2 IgG. Data on COVID-19 disease, demographics/therapeutics and clinical features of the IBD population were collected. IgG ≥ 7 was set for SARS-CoV-2 antibody positivity. Throat swab was performed in cases of IgG positivity. Correlations between antibody positivity or COVID-19 symptoms and therapeutic/clinical data were assessed. In total, 103 IBD patients were enrolled. Among them, 18.4% had IgG ≥ 7. Multivariate analysis of antibody positivity correlated only with IBD treatment. For IgG ≥ 7, the odds ratio was 1.44 and 0.16 for azathioprine and mesalazine, respectively, The IBD population does not have a higher risk of severe COVID-19. The relative risk of having SARS-CoV-2 antibodies and symptoms was higher for patients taking azathioprine, then biologic therapy and lastly mesalazine. None of the patients under biologic therapy developed severe COVID-19.
Sections du résumé
BACKGROUND
BACKGROUND
Guidelines recommend to cease inflammatory bowel disease (IBD) biologic therapy during coronavirus disease 2019 (COVID-19).
AIM
OBJECTIVE
To investigate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody positivity in an IBD cohort, COVID-19 disease severity and to evaluate the correlation with clinical/therapeutic variables.
METHODS
METHODS
Prospective observational cohort study. IBD patients were tested for SARS-CoV-2 IgG. Data on COVID-19 disease, demographics/therapeutics and clinical features of the IBD population were collected. IgG ≥ 7 was set for SARS-CoV-2 antibody positivity. Throat swab was performed in cases of IgG positivity. Correlations between antibody positivity or COVID-19 symptoms and therapeutic/clinical data were assessed.
RESULTS
RESULTS
In total, 103 IBD patients were enrolled. Among them, 18.4% had IgG ≥ 7. Multivariate analysis of antibody positivity correlated only with IBD treatment. For IgG ≥ 7, the odds ratio was 1.44 and 0.16 for azathioprine and mesalazine, respectively,
CONCLUSION
CONCLUSIONS
The IBD population does not have a higher risk of severe COVID-19. The relative risk of having SARS-CoV-2 antibodies and symptoms was higher for patients taking azathioprine, then biologic therapy and lastly mesalazine. None of the patients under biologic therapy developed severe COVID-19.
Identifiants
pubmed: 35432745
doi: 10.4253/wjge.v14.i3.153
pmc: PMC8984534
doi:
Types de publication
Journal Article
Langues
eng
Pagination
153-162Informations de copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: No conflict of interest.
Références
Obes Rev. 2020 Jun;21(6):e13034
pubmed: 32281287
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):525-527
pubmed: 32311321
J Med Virol. 2020 Jun;92(6):680-682
pubmed: 32124995
J Crohns Colitis. 2020 Sep 16;14(9):1334-1336
pubmed: 32215548
Cell Immunol. 2020 Jul;353:104114
pubmed: 32361409
Gastroenterology. 2020 Jul;159(1):81-95
pubmed: 32251668
Am J Gastroenterol. 2020 Jul;115(7):1003-1006
pubmed: 32618648
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Gastroenterology. 2020 Jul;159(1):350-357
pubmed: 32283100
Clin Chim Acta. 2020 Oct;509:1-7
pubmed: 32485157
Clin Chem. 2020 Nov 1;66(11):1405-1413
pubmed: 32777031
Lancet Gastroenterol Hepatol. 2020 May;5(5):434-435
pubmed: 32199469
Clin Gastroenterol Hepatol. 2020 Nov;18(12):2689-2700
pubmed: 32777550
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
J Transl Med. 2020 Apr 14;18(1):165
pubmed: 32290847
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
Gut. 2020 Jul;69(7):1213-1217
pubmed: 32354990
J Infect Public Health. 2020 Sep;13(9):1202-1209
pubmed: 32718894
Gastroenterology. 2020 Jul;159(1):371-372
pubmed: 32247695
Pulmonology. 2021 Jan-Feb;27(1):52-66
pubmed: 32713784
Dig Liver Dis. 2020 Aug;52(8):816-818
pubmed: 32601027
Chin Med J (Engl). 2020 May 5;133(9):1039-1043
pubmed: 32118639
Gut. 2020 Jul;69(7):1335-1342
pubmed: 32303609